Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revised dosing of ciprofloxacin for patients with impaired renal function
2024-520379-28-00Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ciprofloxacin in bacterial disease, sponsored by Amsterdam University Medical Center. Primary endpoint: Drug exposure in the first 24 hours of treatment (AUC0-24). Planned start Jan 2025; status: authorised.
02
Drugs
ciprofloxacin
03
Conditions
bacterial disease
Beyond the preview
Go deeper on 2024-520379-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520379-28-00.